Gilead Sciences and Achillion are axing a joint development program for an experimental hepatitis C therapy after GS 9132 demonstrated an increased risk of kidney failure in an early/mid-stage trial. Researchers were concerned by signs of an increase in serum creatinine levels in volunteers, though they said the increases were reversible after dosing. Both companies, however, added that they would continue to focus on other NS4A antagonists after seeing positive data on efficacy. Release | Report